The DOI matches its Crossref record.
Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers
Abstract
Orlistat, an inhibitor of gastrointestinal lipases, limits the absorption of ingested fat and could become a potential treatment for obesity. This analysis was performed to elucidate the relationship between orlistat dose and intensity of inhibition of dietary fat absorption (assessed by measuring fecal fat excretion). In 11 phase I double-blind, placebo-controlled, parallel-group randomized studies, a total of 171 subjects received oral daily doses that ranged from 30 to 1200 mg orlistat or matching placebo three times a day for 9 to 10 days. The results of the daily mean fecal fat excretion percentage (relative to ingested fat) were correlated to the orlistat daily dose. A simple maximum-effect model that included a basal value was used to fit the dose-response relationship for all evaluable subjects. The mean maximum percentage of ingested fat excreted in the feces was approximately 32% during orlistat administration compared with 5% during placebo administration. The orlistat daily dose that produced 50% of the maximum effect was 98 mg/day. The model-fitting suggests the existence of a steep portion of the dose-response curve up to approximately 400 mg/day, with a subsequent tendency to plateau at higher doses. Such an analysis was instrumental in identifying appropriate doses to be used in therapeutic trials for weight loss in obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Barlow, S. E., & and the Expert Committee (2007) · Pediatrics · doi:10.1542/peds.2007-2329c · Cited by 4,497
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Recommendations for Treatment of Child and Adolescent Overweight and Obesity
Spear, B. A., Barlow, S. E., Ervin, C., Ludwig, D. S., Saelens, B. E., Schetzina, K. E., & Taveras, E. M. (2007) · Pediatrics · doi:10.1542/peds.2007-2329f · Cited by 856
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
“Orlistat limits the digestion and absorption of triglycerides in the GI tract (12) and subsequently causes the excretion of about 30% of ingested fat (13).”
BackgroundOrlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00005 · Cited by 434
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Orlistat in the long-term treatment of obesity in primary care settings.
Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367
Self-citationCurrent and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 331
Finer, N., James, W., Kopelman, P., Lean, M., & Williams, G. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801128 · Cited by 325
Ros, E. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00456-1 · Cited by 316
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1108 · Cited by 287
Self-citationAGA technical review on obesity
Klein, S., Wadden, T., & Sugerman, H. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35514 · Cited by 274
Current treatments for obesity
Ruban, A., Stoenchev, K., Ashrafian, H., & Teare, J. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-3-205 · Cited by 266
Orlistat Inhibits Dietary Cholesterol Absorption
Mittendorfer, B., Ostlund, R. E., Patterson, B. W., & Klein, S. (2001) · Obesity Research · doi:10.1038/oby.2001.79 · Cited by 114
MicroRNAs in brown and beige fat
Goody, D., & Pfeifer, A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.05.003 · Cited by 54
How effective are lifestyle changes in the prevention of type 2 diabetes mellitus?
Pi-Sunyer, F. X. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00287.x · Cited by 40
Compliance, Behavior Change, and Weight Loss With Orlistat in an Over‐the‐Counter Setting
Schwartz, S. M., Bansal, V. P., Hale, C., Rossi, M., & Engle, J. P. (2008) · Obesity · doi:10.1038/oby.2007.96 · Cited by 36
Zoss, I., Piec, G., & Horber, F. F. (2002) · Obesity Surgery · doi:10.1381/096089202321144685 · Cited by 34
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“At full dose, orlistat blocks absorption of 30% of the ingested fat.(120) Clinical efficacy: Orlistat is one of the most studied weight loss medication, with several randomized trials and meta-analyses.”
BackgroundFabbrini, E., & Klein, S. (2008) · Clinical Cornerstone · doi:10.1016/s1098-3597(08)60027-7 · Cited by 9
Metadata
- Authors
- Zhi, J., Melia, A. T., Guerciolini, R., Chung, J., Kinberg, J., Hauptman, J. B., & Patel, I. H.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1994-07
- Volume
- 56
- Issue
- 1
- Pages
- 82-85
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2136520528
- Cited by
- 278
- References
- 0
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.